



Synta to Host Investor Meeting and Webcast at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2013

LEXINGTON, Mass.--(BUSINESS WIRE)--May. 31, 2013-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will host an investor meeting and webcast to discuss interim results from the GALAXY-1 trial, a randomized Phase 2b/3 study designed to evaluate ganetespib in combination with docetaxel for the treatment of advanced non-small cell lung cancer at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place May 31 – June 4 in Chicago.

The meeting will take place on Monday, June 3, 2013, from 6:45 p.m. to 7:45 p.m. CDT, and will include management and data presentations followed by a question and answer session with key opinion leaders.

The meeting will be webcast beginning at 7:00 p.m. CDT. An accompanying slide presentation, live webcast, and replay of the event will be available on the home page of the Company's website, www.syntapharma.com.

About Ganetespib

Ganetespib, an investigational drug candidate, is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression. Many solid and hematologic tumors are dependent on Hsp90 client proteins including proteins involved in “oncogene addiction” (ALK, HER2, mutant BRAF and EGFR, androgen receptor, estrogen receptor, JAK2); proteins involved in resistance to chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1, survivin, and WEE1); proteins involved in angiogenesis (HIF-1alpha, VEGFR, PDGFR, and VEGF); and proteins involved in metastasis (MET, RAF, AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical models, inhibition of Hsp90 by ganetespib results in the inactivation, destabilization, and eventual degradation of these cancer-promoting proteins. Ganetespib is being evaluated in over 20 clinical trials including trials in lung, breast, colorectal, and hematologic malignancies. Information on these trials can be found at www.clinicaltrials.gov.

About the GALAXY Program

The GALAXY (Ganetespib Assessment in Lung cAncer with docetaXeI) program consists of two randomized trials comparing the combination of ganetespib and docetaxel versus docetaxel alone in patients with Stage IIIB/IV NSCLC who have received one prior systemic therapy: a 300-patient Phase 2b/3 trial (GALAXY-1) to determine the patient population most likely to derive benefit from ganetespib, and a 500-patient confirmatory Phase 3 trial (GALAXY-2). More information about the GALAXY trials can be found at www.clinicaltrials.gov (NCT01348126 and NCT01798485).

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

Source: Synta Pharmaceuticals Corp.

Investor Relations Contact:

Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213
gfarmer@syntapharma.com

or

Argot Partners
Andrea Rabney, 212-600-1494
andrea@argotpartners.com

or

Media Contact:

Q Communications
Eliza Schleifstein, 973-361-1546
efschleifstein@gmail.com